Thermo Fisher Scientific Inc. (TMO)
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Last price
- $673.20
- As of
Kresmion compiles this page from TMO's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
THERMO FISHER SCIENTIFIC INC. (TMO): 7 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-07-31.
See the full TMO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TMO on one page. Preview it with sample data, then open it live with a free account.
Preview the TMO dossierActive signals for TMO
- highCONSENSUS_BUY
3 tracked funds increased TMO this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +63% to TMO (2026Q2)
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +2104% to TMO (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +134% to TMO (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +128227% to TMO (2026Q2)
FREE, NO ACCOUNT
Every signal on TMO, as it fires
You are seeing 5 of 36 signals recorded on TMO since 2026-05-05.
The five above landed across 2 days. The other 31 were recorded on 2 other days. 34 of the 36 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in TMO (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| VIKING GLOBAL INVESTORS LPCUSIP 883556102 · 2026Q2 | $971.3M | 2.77% | , |
| D. E. Shaw & Co., Inc.CUSIP 883556102 · 2026Q2 | $321.7M | 0.15% | , |
| CITADEL ADVISORS LLCCUSIP 883556102 · 2026Q2 | $288.3M | 0.03% | , |
| Point72 Asset Management, L.P.CUSIP 883556102 · 2026Q2 | $139.2M | 0.15% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 883556102 · 2026Q2 | $83M | 0.03% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 883556102 · 2026Q2 | $8.5M | 0.01% | , |
| Bridgewater Associates, LPCUSIP 883556102 · 2026Q2 | $6.5M | 0.03% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TMO
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
TMO against its peers
TMO's operating margin of 17.4% ranks in the 73rd percentile of 23 Life Sciences Tools & Services sub-industry peers, fiscal periods ending between 2025-10-31 and 2026-06-30.
| Metric | TMO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 44.6B USD | 1.2B USD | 98 | 25 |
| Gross margin | n/a | 57.3% | n/a | 12 |
| Operating margin | 17.4% | -3.8% | 73 | 23 |
| Net margin | 15.0% | -3.6% | 79 | 25 |
| Return on equity | 12.6% | -5.0% | 74 | 24 |
| P / E | 37.9x | 44.5x | 13 | 11 |
| 1 year | 28.0% | 27.9% | 52 | 25 |
Peers (25): DHR, A, IQV, WAT, ILMN, MTD, MEDP, CRL, TEM, TECH, RGEN, AVTR, TXG, BRKR, SHC, ADPT, ABCL, FTRE, MRVI, DNA, MLAB, CTKB, OABI, PACB, CDXS. Fiscal periods ending between 2025-10-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (TMO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow TMO on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to TMO for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.